Fecal Microbiota Transfer Protocol for Core ASD Symptom Reduction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There are no FDA-approved treatments for reducing or eliminating the core symptoms of autism spectrum disorder, and existing medications only address irritability in individuals with ASD.

Innovation Solution

Administering a fecal microbiota transfer therapy (MTT) involving antibiotics and a bowel cleanse followed by a fecal microbiota preparation to restore gut microbiota balance.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If conventional medications (risperidone, aripiprazole) are used to treat ASD, then irritability is reduced, but core autism symptoms remain untreated and treatment options are limited

Engineering Contradiction:

Improvetreatment optionsVSAvoideffectiveness

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent changes the fundamental parameter of treatment approach from pharmacological (chemical) to probiotic (biological). By introducing fecal microbiota preparation, the treatment targets the gut-brain axis to modulate neurobehavioral symptoms, representing a paradigm shift in how ASD is treated.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses the gut microbiota as an intermediary mechanism to treat ASD. The fecal microbiota preparation acts as a mediator that influences brain function and behavior through the gut-brain axis, providing a indirect but effective treatment pathway.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If fecal microbiota transfer therapy is administered to restore gut microbiota balance, then ASD symptoms and GI issues are reduced, but the treatment protocol complexity increases

Engineering Contradiction:

Improvesymptom reductionVSAvoidtreatment protocol

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent incorporates preliminary actions including antibiotic administration and bowel cleanse before the main fecal microbiota preparation treatment. These preparatory steps are designed to optimize the recipient's gut environment to enhance the efficacy of the subsequent microbiota transfer.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The treatment protocol is segmented into distinct phases: preliminary treatment (antibiotics, bowel cleanse), main treatment (fecal microbiota preparation), and follow-up assessment. This segmentation allows for systematic implementation and easier monitoring of treatment effects.

Inventive Principle:

Principle #1Segmentation

3Measurement precision

If standardized rating scales are used to assess ASD symptom severity, then treatment effectiveness can be measured, but the assessment process becomes more complex

Engineering Contradiction:

Improvesymptom severity assessmentVSAvoidassessment system

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent employs standardized rating scales that serve multiple functions: baseline assessment, treatment monitoring, and outcome evaluation. These universal assessment tools can be applied across different treatment studies and patient populations, providing consistent measurement without requiring custom assessment protocols.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Significant reduction in ASD symptom severity, including gastrointestinal issues, achieved through a 10-90% improvement in ASD symptom severity and 40% reduction in GI symptoms, as assessed by standardized rating scales.

Implementation Method 1

transferring beneficial fecal bacteria to replace, restore, or rebalance the ASD patient's gut microbiota

Methodology Applied

Scientific EffectFecal Microbiota Transfer:

Implementation Method 2

administering an antibiotic to an autistic human subject

Methodology Applied

Scientific EffectAntibacterial action:

Implementation Method 3

subjecting the autistic human subject to a bowel cleanse

Methodology Applied

Scientific EffectBowel cleanse:

Data Source

PatentUS20260027166A1Methods for treating autism spectrum disorder and associated symptoms

Publication Date: 2026.01.29 FINCH THERAPEUTICS HLDG LLC

AI summary

The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.